Fig. 4From: Mathematical model on Alzheimer’s diseaseTreatment with etanercept (decreasing T α degradation rate by 10 fold), TGF- β injection (increasing its constitutive source by 10 fold), aducanumab (increasing the clearance rate of \(A_{\beta }^{o}\) by 10 fold), and bindarit (increasing MCP-1 natural degradation by 10 fold). In a, the profiles of no treatment, bindarit and aducanumab coincide. In b, no treatment and bindarit coincide. The lowest curve in Fig. 4 a, and the highest curve in Fig. 4 b, correspond to the case where the curves of no treatment and several other drugs coincide; these drugs have negligible efficacyBack to article page